Wellington Management Group LLP Sells 82,958 Shares of Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Wellington Management Group LLP has reduced its stock holdings in Vanda Pharmaceuticals by 23.8%, selling 82,958 shares and now owning approximately 0.45% of the company valued at $1.22 million.
• Several institutional investors have made significant changes to their positions, with Millennium Management LLC increasing its holdings by 67.4% recently.
• Vanda Pharmaceuticals reported a disappointing earnings quarter with an EPS of ($0.46), missing estimates, and is expected to post a negative EPS of ($1.12) for the current year.

Wellington Management Group LLP trimmed its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 23.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,888 shares of the biopharmaceutical company's stock after selling 82,958 shares during the period. Wellington Management Group LLP owned 0.45% of Vanda Pharmaceuticals worth $1,220,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 3,370 shares during the period. ProShare Advisors LLC lifted its position in Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock valued at $90,000 after purchasing an additional 4,599 shares during the period. Northern Trust Corp boosted its holdings in shares of Vanda Pharmaceuticals by 1.3% in the 4th quarter. Northern Trust Corp now owns 507,442 shares of the biopharmaceutical company's stock valued at $2,431,000 after buying an additional 6,283 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Vanda Pharmaceuticals by 28.0% in the fourth quarter. Wells Fargo & Company MN now owns 33,509 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 7,339 shares during the period. Finally, Tudor Investment Corp ET AL lifted its stake in Vanda Pharmaceuticals by 59.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company's stock valued at $118,000 after buying an additional 9,180 shares during the period. Institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Stock Down 0.7%

VNDA traded down $0.03 during trading on Friday, reaching $4.61. 79,942 shares of the company were exchanged, compared to its average volume of 559,002. The company's 50-day moving average is $4.64 and its two-hundred day moving average is $4.54. Vanda Pharmaceuticals Inc. has a 12-month low of $3.81 and a 12-month high of $5.55. The company has a market cap of $272.23 million, a price-to-earnings ratio of -4.08 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.12). The firm had revenue of $52.59 million during the quarter, compared to the consensus estimate of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Finally, Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Strong Buy" and an average target price of $16.50.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director directly owned 97,082 shares of the company's stock, valued at approximately $445,606.38. This trade represents a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.